← Eichor
Study identifier: NCT05625633 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Condition: Warts  ·  Sponsor: Western Institute for Veterans Research

PhasePhase 2/Phase 3
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

This description comes directly from the study's public registry record.

Talk to the study team

Lowell Nicholson, MD  ·  801-581-2121  ·  lowell.nicholson@hsc.utah.edu

Jamie Rhoads, MD  ·  801-581-2121  ·  jamie.rhoads@hsc.utah.edu

Always discuss trial participation with your own doctor first.

Locations (2)

University of Utah Midvalley Health CenterSalt Lake City, Utah, United StatesRecruiting
VA Salt Lake City Health Care SystemSalt Lake City, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05625633